Literature DB >> 19423368

A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom.

K Ki Pang1, Carlos de Sousa, Bethan Lang, Michael G Pike.   

Abstract

The incidence, mode of presentation and management of Dancing Eye Syndrome/Opsoclonus-Myoclonus Syndrome (DES/OMS) was prospectively evaluated in 20 United Kingdom (UK) paediatric neurology centres by questionnaire over a 24-month period between 2003 and 2005. Nineteen children were notified, giving an incidence of 0.18 cases per million total population per year. Mean age at presentation was 18 months (range 3-42 months). Fifteen families consented to participate in the study. Atypical features were present in 6/15 cases including very delayed presentation of opsoclonus, dysphagia, and rapid spontaneous improvement without treatment. Only 4/15 cases were associated with neuroblastoma (NB) but current practice in excluding this is diverse and a standardised approach is suggested. 2009 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423368     DOI: 10.1016/j.ejpn.2009.03.002

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  18 in total

1.  Incidence, ocular manifestations, and survival in children with neuroblastoma: a population-based study.

Authors:  Stephen J Smith; Nancy N Diehl; Brian D Smith; Brian G Mohney
Journal:  Am J Ophthalmol       Date:  2010-02-10       Impact factor: 5.258

2.  Paraneoplastic neurologic disorders in children.

Authors:  Elizabeth M Wells; Josep Dalmau
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

3.  Opsoclonus myoclonus ataxia syndrome following COVID-19 infection.

Authors:  Ismail Ibrahim Ismail; Walaa A Kamel; Ayman Kilany
Journal:  Acta Neurol Belg       Date:  2022-07-14       Impact factor: 2.471

4.  Adult-onset opsoclonus-myoclonus-ataxia syndrome as a manifestation of brazilian lyme disease-like syndrome: a case report and review of literature.

Authors:  Angelina Maria Martins Lino; Raphael Ribeiro Spera; Fernando Peixoto Ferraz de Campos; Christian Henrique de Andrade Freitas; Márcio Ricardo Taveira Garcia; Leonardo da Costa Lopes; Aleksander Snioka Prokopowitsch
Journal:  Autops Case Rep       Date:  2014-03-31

5.  Neuroblastoma presenting as opsoclonus-myoclonus: A series of six cases and review of literature.

Authors:  Jagdish P Meena; Rachna Seth; Biswaroop Chakrabarty; Sheffali Gulati; Sandeep Agrawala; Priyanka Naranje
Journal:  J Pediatr Neurosci       Date:  2016 Oct-Dec

6.  Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

Review 7.  Update on opsoclonus-myoclonus syndrome in adults.

Authors:  Sun-Young Oh; Ji-Soo Kim; Marianne Dieterich
Journal:  J Neurol       Date:  2018-11-27       Impact factor: 4.849

8.  Clinical responses to rituximab in a case of neuroblastoma with refractory opsoclonus myoclonus ataxia syndrome.

Authors:  Samin Alavi; Ali Kord Valeshabad; Borhan Moradveisi; Ali Aminasnafi; Mohammad Taghi Arzanian
Journal:  Case Rep Oncol Med       Date:  2012-11-06

9.  Opsoclonus-myoclonus syndrome after adenovirus infection.

Authors:  Steffen Syrbe; Andreas Merkenschlager; Matthias K Bernhard; Jens Grosche; Uwe Gerd Liebert; Wolfgang Hirsch; Wolfgang Härtig
Journal:  Springerplus       Date:  2015-10-23

10.  Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

Authors:  Pedro A de Alarcon; Katherine K Matthay; Wendy B London; Arlene Naranjo; Sheena C Tenney; Jessica A Panzer; Michael D Hogarty; Julie R Park; John M Maris; Susan L Cohn
Journal:  Lancet Child Adolesc Health       Date:  2017-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.